IXICO signs new contract for specialist imaging clinical trial services
Expansion of customer base, and endorsement of IXICO’s expertise in providing both PET and MR imaging services in neuroscience clinical trials
IXICO today announces that it has signed a new contract for specialist imaging clinical trial services. The contract is for a Phase II clinical trial of patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease (AD). Sponsored by specialist Spanish biotech company Araclon Biotech, a Grifols company, this phase II of the study is designed to establish the dosage regimen for the therapy, as well as confirm the treatment safety and tolerability data obtained in phase I.
Using our TrialTracker™ digital platform, IXICO will collate both PET and MRI scans acquired at specialist imaging centres across Europe. This data will be then analysed using IXICO’s patent protected image analysis technology, which has been customised to evaluate patient eligibility, assess target engagement and quantify drug effects in AD patients.
For further information please contact:
Giulio Cerroni, Chief Executive Officer
Susan Lowther, Chief Financial Officer
+44 20 3763 7499
Shore Capital (Nomad and Broker)
Bidhi Bhoma / Edward Mansfield / James Wolfe
+44 20 7408 4090
FTI Consulting Limited (Investor Relations)
Simon Conway / Mo Noonan
+44 20 3727 1000